| PureTech Health–Novartis: mTORC1 inhibitors, 201703– license excl to 2 clin stage programs to be developed by new resTORbio subsidary |
2017-03-24 |
| Numares–Univ Oxford: NMR-based IVD tests, 201703– collab developm of multiple sclerosis test using Axinon IVD system + MGS technology |
2017-03-23 |
| BASF–MIT: CRISPR technology, 201703– license ww for agricultural + industrial microbiology applications from Broad Institute |
2017-03-22 |
| Symetis–SEVERAL: investment, 201703 IPO at Euronext NOT REALISED because of acquistion offer by Boston Scientific |
2017-03-17 |
| Medac–Cevec: rec protein production technology, 201703– license to CAP GT technology for oncology products |
2017-03-16 |
| Provecs–Cevec: rec protein production technology, 201703– license non-excl extension to CAP GT technology for cancer immunotherapy |
2017-03-16 |
| CRISPR Therapeutics–MaxCyte: gene transfer technology, 201703– license non-excl to CRISPR Tx + Caseio for using Flow Electroporation technology |
2017-03-14 |
| NeoGenomics–AstraZeneca: cancer research tests, 201703– collab using automated Definiens biomarker solutions for IHC services of NeoGenomics |
2017-03-13 |
| ILC Micro-Chem–SGS: investment, 201703 acquisition of ILC by SGS |
2017-03-09 |
| Breath Therapeutics–Gimv: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–MC Services: public relations, 201703 service existent by MC Services AG |
2017-03-08 |
| Breath Therapeutics–SEVERAL: investment, 201703 financing round Series A €43.5m co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Breath Therapeutics–Sofinnova: investment, 201703 financing round Series A totalling €43.5m incl co-led by Gimv + Sofinnova Partners |
2017-03-08 |
| Fresenius–Wacker: rec protein production, 201703 collab use of Wacker Biotech’s FOLDTEC technology to produce Fabs for Fresenius |
2017-03-08 |
| Illumina–Endress+Hauser: automated liquid handling, 201703– collab developm + marketing of AJ CyBio FeliX system with Infinium XT BeadChip |
2017-03-08 |
| InGeneron–Sanford Health: investment, 201703– tranched investment Series D $20m from Sanford Health |
2017-03-06 |
| Alcami–Bruker: X-ray technology, 201703 supply of D8 Discover HTS XRD system to Alcami site in Weert NL |
2017-03-03 |
| Essen BioScience–Sartorius: investment, 201703–201704 acquisition $320m in cash of Essen BioScience from SFW Capital Partners |
2017-03-03 |
| Neurovance–Novartis: investment, –201703 existent investment of NVF when acquisition of Neurovance by Otsuka announced |
2017-03-03 |
| Neurovance–Otsuka: investment, 201703– acquisition $100m upfront + $150m milestones of Neurovance by Otsuka America Inc |
2017-03-03 |
| CRISPR Therapeutics–W2O Group: public relations, 201703 service existent by W2O Group |
2017-03-02 |
| CRISPR Therapeutics–Westwicke Partners: public relations, 201703 service existent investor relations by Westwicke Partners |
2017-03-02 |
| Arsanis–Ten Bridge Communications: public relations, 201703 service existent by Ten Bridge |
2017-03-01 |
| Avillion–Merck (DE): Nanobody, 201703– collab ww clinical development + regulatory submission of M1095 anti IL-17 A/F Nanobody |
2017-03-01 |
| Axolabs–LGC: investment, 201703 acquisition of Axolabs GmbH by LGC |
2017-03-01 |
| InfanDx–Arnika Beteiligungen: investment, 201703 investment by new investor Arnika Beteiligungen GmbH |
2017-03-01 |
| Omeicos–SEVERAL: investment, 201703 1st closing €8.3m of financing round Series B led by Vesalius Biocapital II |
2017-03-01 |
| Addex–SEVERAL: investment, 201702 private placement CHF3m with 1.5m treasury shares at CHF2/share led by Herculis Partners SA |
2017-02-28 |
| Sanofi–Lonza: rec protein production, 201703– collab 50/50 jv to establish biologics production facility in CH w initial investment of CHF290 (€270m) |
2017-02-27 |
| Adaptimmune–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Galenica–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Nabriva–Ally Bridge Group: investment, 201702 investment €na by ABG |
2017-02-23 |
| Tesaro–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| WuXi PharmaTech–Ally Bridge Group: investment, 201702 existent investment of ABG |
2017-02-23 |
| Neovacs–ActeaVentures: business consulting, 201702 supply service business development advisor for Neovacs license deal w BioSense Global LLC |
2017-02-21 |
| Bayer–Yara: digital farming, 201702– collab + license ww to ImageIT mobile imaging technology for plant monitoring + farming recommendations |
2017-02-20 |
| Oncgnostics–Thuringia (govt): investment, 201702 additional investment of €500k from bm|t |
2017-02-20 |
| Univ Warwick–Bruker: NMR spectrometer, 201702 supply existent of Bruker 850 WB US² system at NMR Facility |
2017-02-17 |
| BioMedPartners–SEVERAL: investment, 201702 first closing CHF75m of BioMedInvest III fund incl cornerstone investor EIF + Berner Kantonalbank |
2017-02-16 |
| Selecta Biosciences–Lonza: gene therapy products, 201702– supply contract manufacturing of Anc80-AAV-based gene therapy product by Lonza Houston Inc |
2017-02-16 |
| Boehringer–Cornell Univ: drug discovery, 201702– collab 3y identify COPD treatm approaches Weill Cornell Medicine Dept of Genetic Medicine |
2017-02-15 |
| Boehringer–Inventiva: pharmaceutical, 201702 collab RnD existent |
2017-02-15 |
| Jecure Therapeutics–Versant Ventures: investment, 201702 financing round Series A $20m from founding investor Versant Ventures |
2017-02-15 |
| Immunicum–MacDougall Biomedical Communications: public relations, 201702 service existent by MacDougall |
2017-02-13 |
| Santhera–SEVERAL: credit, 201702–202202 senior unsecured convertible bonds CHF60m 5% due 202202 |
2017-02-10 |
| Evotec–Novo Group: investment, 201702 strategic investment of €90.3m 13.15m new Evotec shares at €6.87/share resulting in 8.9% ownership by Novo A/S |
2017-02-09 |
| NewLink Genetics–Cevec: rec protein production technology, 201702– license €na to CAP GT + CAP Go cell lines for Zika vaccine developm + commerc |
2017-02-09 |
| Albany Molecular–Bruker: mass spectrometer, 201702 supply MALDI PharmaPulse system to AMRI by Bruker Daltonics + HighRes Biosolutions |
2017-02-07 |
| Atriva Therapeutics–High-Tech Gründerfonds: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF |
2017-02-07 |
| Atriva Therapeutics–SEVERAL: investment, 201702 seed financing round led by Stichting Participatie Atriva + HTGF plus private investors |
2017-02-07 |
| Atriva Therapeutics–Stichting Participatie Atriva: investment, 201702 seed financing round led by SPA + HTGF |
2017-02-07 |
| Bruker–Albany Molecular: mass spectrometry, 201702– collab developm of HTS applications using MALDI PharmaPulse system from Bruker + HighRes |
2017-02-07 |
| Labor Limbach–Numares: NMR-based IVD tests, 201702 collab existent Labor Limbach offers IVD test LipoComplete |
2017-02-07 |
| Prexton Therapeutics–Forbion: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Merck (DE): investment, 201702 financing round Series B totalling €29m incl returning co-investor Merck Ventures |
2017-02-07 |
| Prexton Therapeutics–Seroba: investment, 201702 financing round Series B totalling €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–SEVERAL: investment, 201702 financing round Series B €29m co-led by new investors Forbion + Seroba |
2017-02-07 |
| Prexton Therapeutics–Sunstone Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Sunstone Capital |
2017-02-07 |
| Prexton Therapeutics–Ysios Capital: investment, 201702 financing round Series B totalling €29m incl returning co-investor Ysios Capital |
2017-02-07 |
| Bruker–Endress+Hauser: mass spec sample preparation, 201702 collab Analytik Jena uHTS MALDI sample prep for rapifleX MALDI Pharma Pulse MS |
2017-02-06 |
| GSK–Bruker: mass spectrometer, 201702 supply existent MALDI PharmaPulse 2.0 incl rapifleX MALDI-TOF System at GSK Platform Tech + Science group |
2017-02-06 |
| Wilex–Hopp Group: investment, 201702– financing commitment of up to €10m by Dievini Hopp [not announced whether credit or investment] |
2017-02-06 |
| Coral BioNet–UV-Cap: investment, 201702 acquisition 100% of Scil Proteins GmbH from Bionet Ventures GmbH by UV-Cap GmbH & Co KG |
2017-02-03 |
| Leukocare–Rentschler: investment, 201702 acquisition of 10% stake in Leukocare AG by Rentschler Biotechnologie GmbH as part of strategic alliance |
2017-02-02 |
| Ottobock–Steeper: prosthetic, 201702 acquisition of BeBionic hand product range by Ottobock from Steeper |
2017-02-02 |
| Rentschler–Leukocare: drug formulation technology, 201702– collab strategic alliance using SPS technology for biopharmaceuticals |
2017-02-02 |
| Immunic–Saxony-Anhalt (govt): investment, 201702 investment Series A €4m by new investor IBG bringing total to €21.7m |
2017-02-01 |
| Lonza–SEVERAL: investment, 201701–201702 capital increase CHF865m placing 5m new shares at CHF173/share to selected/qualified investors |
2017-01-31 |
| Regeneron–Indivumed: tissue banking, 201701– collab + supply €na tissue samples w clinical + molecular data for cancer research |
2017-01-31 |
| Medizinsches Labor Bremen–Sonic Healthcare: investment, 201701– acquisition for €63m (cash + debt free) of MLB by Sonic Healthcare Ltd |
2017-01-30 |
| ProteomeTools project–BioNTech: proteomics, 201701 collab existent JPM Peptide Technologies is project partner |
2017-01-30 |
| ProteomeTools project–SAP: proteomics, 201701 collab existent SAP is project partner |
2017-01-30 |
| ProteomeTools project–Thermo Fisher: proteomics, 201701 collab existent Thermo Fisher Scientific is project partner |
2017-01-30 |
| ProteomeTools project–TU Munich: proteomics, 201701 collab existent TUM is coordinating project partner in developing PROPEL library |
2017-01-30 |
| SGS–SEVERAL: credit, 201701–202601 nine year CHF375m straight bond with coupon of 0.55% |
2017-01-30 |
| Sonic Healthcare–McDermott Will & Emery: legal services, 201701 advisor for acquisition of Medical Lab Bremen by Sonic Healthcare Ltd |
2017-01-30 |
| United Kingdom (govt)–Qiagen: genomic database, 201701– Genomics England to use HGMD Online Professional solution for 100,000 Genomes Project |
2017-01-30 |
| Cellestia Biotech–PPF Group: investment, 201701 seed financing round Series C totalling CHF5.2m incl Sotio/PPF Group + private investors |
2017-01-26 |
| Cellestia Biotech–SEVERAL: investment, 201701 seed financing round Series C CHF5.2m from Sotio/PPF Group + private investors |
2017-01-26 |
| Actelion–Enamine: chemical compound library, 201701– collab expansion supply of screening compound library to Actelion |
2017-01-23 |
| Merck (DE)–Domain Therapeutics: cancer drugs, 201701– collab developm + ww license to adenosine receptor antagonists |
2017-01-23 |
| Affimed–SEVERAL: investment, 201701 public offering $18m + $2.7m with 10m+1.5m common shares at $1.8/share |
2017-01-19 |
| Asahi Kasei–Evotec: drug discovery, 201701– supply service €na expansion into integrated drug discovery collab for inhibitors of ion channel targets |
2017-01-19 |
| Fibrocor Therapeutics–Evotec: drug discovery services, 201701– collab developm fibrosis drugs w all drug discovery activities done by Evotec |
2017-01-17 |
| Fibrocor Therapeutics–Evotec: investment, 201701 Evotec to receive equity stake in Fibrocor as part of collaboration |
2017-01-17 |
| Fibrocor Therapeutics–SEVERAL: investment, 201701 seed financing C$2.8m ($2.1m) incl cash from co-founder MaRS Innovation |
2017-01-17 |
| Mologen–SEVERAL: credit, 201701–202501 convertible bonds €4.99m at 6% incl major shareholder GTD |
2017-01-17 |
| Northwell Health–Indivumed: tissue bank, 201701– collab to create cancer research biobank |
2017-01-17 |
| Luxendo–Huntsworth: public relations, 201701 service existent by Citigate Dewe Rogerson |
2017-01-12 |
| Luxendo–SEVERAL: investment, 201701 financing round Series A extension €2m bringing total to €8m co-led by LSP + EMBL Ventures + EMBLEM |
2017-01-12 |
| Merck (DE)–Palantir: data integration and analysis s/w, 201701– collab €na use initially in healthcare ultimately in all 3 business sectors of Merck |
2017-01-12 |
| Crescendo Biologics–Genedata: bioinformatics, 201701– license to Genedata Biologics as workflow platform for internal + partnered Humabody programs |
2017-01-10 |
| Amgen–Immatics: cancer immunotherapy, 201701– strategic collab $30m upfront + $500m milestones + royalties combining Xpresident + BiTE technologies |
2017-01-09 |
| Arrowhead–Silence Therapeutics: investment, 201701 acquisition 6.83m common shares = 9.21% shareholding for $11.3m |
2017-01-09 |
| Epidarex Capital–Lilly: investment, 201701 existent one of several investors in Epidarex is Eli Lilly |
2017-01-09 |
| Eternygen–Berlin (govt): investment, 201701 financing round Series A totalling €8m incl co-investor VC Fonds Technologie managed by IBB |
2017-01-09 |
| Eternygen–Epidarex Capital: investment, 201701 financing round Series A totalling €8m incl lead investor Epidarex Capital |
2017-01-09 |
| Eternygen–Evotec: investment, 201701 financing round Series A totalling €8m incl co-investor Evotec AG |
2017-01-09 |
| Eternygen–MC Services: public relations, 201701 service existent by MC Services AG |
2017-01-09 |
| Eternygen–SEVERAL: investment, 201701 financing round Series A €8m led by Epidarex Capital plus Evotec + VC Fonds Technologie + 2 family offices et al |
2017-01-09 |
![[LSG] Life-Sciences-Germany.com - The Life Sciences Web Portal for German-speaking Europe](/images/basics/lsg-life-sciences-germany-portal-logo.svg){kind=logo}
1 2 3 ... 41 42 43 44 
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 120x600px](/banner/iito-20181119-120-600-lsus-life-sciences-usa-com.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
